Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Allen

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Methods and Protocols|April 2, 2020
Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study ProtocolJoseph M Norris, Veeru Kasivisvanathan, Clare Allen, et al.
BJU International|March 7, 2018
Three-dimensional printing in robot-assisted radical prostatectomy - an Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) Phase 2a studyPankaj Chandak, Nick Byrne, Hugo Lynch, et al.
BJU International|May 14, 2019
Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?Edward J Bass, Clement Orczyk, Alistair Grey, et al.
The British Journal of Radiology|July 8, 2021
Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?Francesco Giganti, Clare Allen, Vasilis Stavrinides, et al.
Radiology|April 9, 2013
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standardNimalan Arumainayagam, Hashim U Ahmed, Caroline M Moore, et al.
European Radiology|July 30, 2021
Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trialFrancesco Giganti, Eoin Dinneen, Veeru Kasivisvanathan, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
The Journal of Urology|July 24, 2020
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis <i>J Urol</i> 2020; doi: 10.1097/JU.0000000000001157Vasilis Stavrinides, Francesco Giganti, Shonit Punwani, et al.
The Lancet. Oncology|April 20, 2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyHashim U Ahmed, Richard G Hindley, Louise Dickinson, et al.
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Methods and Protocols|April 2, 2020
Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study ProtocolJoseph M Norris, Veeru Kasivisvanathan, Clare Allen, et al.
BJU International|March 7, 2018
Three-dimensional printing in robot-assisted radical prostatectomy - an Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) Phase 2a studyPankaj Chandak, Nick Byrne, Hugo Lynch, et al.
BJU International|May 14, 2019
Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?Edward J Bass, Clement Orczyk, Alistair Grey, et al.
The British Journal of Radiology|July 8, 2021
Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?Francesco Giganti, Clare Allen, Vasilis Stavrinides, et al.
Radiology|April 9, 2013
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standardNimalan Arumainayagam, Hashim U Ahmed, Caroline M Moore, et al.
European Radiology|July 30, 2021
Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trialFrancesco Giganti, Eoin Dinneen, Veeru Kasivisvanathan, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
The Journal of Urology|July 24, 2020
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis <i>J Urol</i> 2020; doi: 10.1097/JU.0000000000001157Vasilis Stavrinides, Francesco Giganti, Shonit Punwani, et al.
The Lancet. Oncology|April 20, 2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyHashim U Ahmed, Richard G Hindley, Louise Dickinson, et al.
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Pageof 13